Department of Colorectal Surgery, University Hospital Waterford, Waterford, Ireland.
Department of Colorectal Surgery, University Hospital Waterford, Waterford, Ireland.
J Surg Res. 2023 Jan;281:275-281. doi: 10.1016/j.jss.2022.08.043. Epub 2022 Oct 8.
Colonic self-expanding metal stents (SEMS) can be used to relieve malignant and benign large bowel obstruction (LBO) as a bridge to surgery (BTS) and for palliation. Guidelines suggest the use of fluoroscopic guidance for deployment. This may be difficult to obtain after hours and in certain centers. We aimed to determine the outcomes of stenting under endoscopic guidance alone.
All patients who underwent SEMS insertion in our tertiary referral center between August 2010 and June 2021 were identified from a prospectively maintained database. Patient demographics (age/gender), disease characteristics (benign versus malignant/location/stage), stenting intent (BTS versus palliative), and outcomes (technical success/stoma/time from stenting to resection/death/study end) were analyzed.
Fifty-three (n = 39, 73.6% male) patients underwent SEMS insertion. Indications included colorectal carcinoma (n = 48, 90.6%), diverticular stricture (n = 3), and gynecological malignancy (n = 2). In five (9.4%) patients (four BTS and one palliative), SEMSs deployment was not completed because of the inability to pass the guidewire. All underwent emergency surgery. In the BTS cohort (n = 29, median 70.4 [range 40.3-91.8] years), 10 patients underwent neoadjuvant chemoradiotherapy. The permanent stoma rate was 20.7% (n = 6). There was no 30- or 90-d mortality. In the palliative cohort (n = 24, median age 77.1 [range 54.4-91.9]), 16 (66.7%) were deceased at the study end. The median time from stenting to death was 5.2 (2.3-7.9) months.
SEMS placed under endoscopic visualization alone, palliatively and as a BTS, had acceptable stoma, morbidity, and mortality rates. These results show that SEMS insertion can be safely performed without fluoroscopy.
结肠自膨式金属支架(SEMS)可用于缓解恶性和良性大肠梗阻(LBO),作为手术(BTS)和姑息治疗的桥梁。指南建议使用透视引导进行部署。但在非工作时间或在某些中心可能难以获得透视引导。我们旨在确定仅在内镜引导下进行支架置入的结果。
从 2010 年 8 月至 2021 年 6 月在我们的三级转诊中心进行 SEMS 插入的所有患者均从一个前瞻性维护的数据库中确定。患者的人口统计学特征(年龄/性别)、疾病特征(良性与恶性/位置/分期)、支架置入目的(BTS 与姑息性)以及结果(技术成功率/造口/支架置入至切除/死亡/研究结束的时间)进行了分析。
53 名(n=39,73.6%为男性)患者接受了 SEMS 插入。适应证包括结直肠癌(n=48,90.6%)、憩室狭窄(n=3)和妇科恶性肿瘤(n=2)。在 5 名(9.4%)患者(4 名 BTS 和 1 名姑息性)中,由于无法通过导丝,SEMS 无法完成置入。所有患者均行急诊手术。在 BTS 组(n=29,中位年龄 70.4[范围 40.3-91.8]岁)中,10 名患者接受了新辅助放化疗。永久性造口率为 20.7%(n=6)。30 天和 90 天死亡率均为 0。在姑息组(n=24,中位年龄 77.1[范围 54.4-91.9]岁)中,16 名(66.7%)患者在研究结束时死亡。支架置入至死亡的中位时间为 5.2(2.3-7.9)个月。
单独在内镜可视化下放置 SEMS 作为姑息治疗和 BTS,造口、发病率和死亡率可接受。这些结果表明,无需透视引导即可安全进行 SEMS 插入。